PFE trades 2.0% below Wall Street's consensus target of $28.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes PFE achieves its forward estimates and maintains a stable P/E multiple of 9.4x. This scenario reflects the blended consensus of 39 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 23, 2026, Pfizer Inc. (PFE) has a Wall Street consensus price target of $28.50, based on estimates from 39 covering analysts. With the stock currently trading at $27.93, this represents a potential upside of +2.0%. The company has a market capitalization of $159.19B.
Analyst price targets range from a low of $26.00 to a high of $31.00, representing a 18% spread in expectations. The median target of $28.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 15 analysts rating the stock as a Buy or Strong Buy,23 rating it Hold, and 1 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, PFE trades at a trailing P/E of 20.5x and forward P/E of 9.4x. Analysts expect EPS to grow +291.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $37.25, with bear and bull scenarios of $23.47 and $49.09 respectively. Model confidence stands at 51/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 JNJJohnson & Johnson | $648.0B | $269.19 | $286.93 | +6.6% | Buy | 23.4x | 40 |
 MRKMerck & Co., Inc. | $372.7B | $150.91 | $158.12 | +4.8% | Buy | 55.0x | 38 |
 ABBVAbbVie Inc. | $468.8B | $265.32 | $287.08 | +8.2% | Buy | 18.9x | 43 |
 LLYEli Lilly and Company | $1.1T | $1170.48 | $1343.07 | +14.7% | Buy | 32.1x | 45 |
 BMYBristol-Myers Squibb Company | $127.1B | $62.25 | $70.00 | +12.4% | Buy | 9.0x | 42 |
 AZNAstraZeneca PLC | $130.5B | $168.37 | $186.67 | +10.9% | Buy | 16.4x | 41 |
 NVSNovartis AG | $268.5B | $141.28 | $153.00 | +8.3% | Hold | 16.1x | 25 |
 AMGNAmgen Inc. | $221.4B | $410.24 | $393.72 | -4.0% | Buy | 17.8x | 41 |
 GILDGilead Sciences, Inc. | $189.6B | $152.67 | $150.00 | -1.7% | Buy | — | 58 |
 BIIBBiogen Inc. | $33.3B | $225.36 | $245.88 | +9.1% | Buy | 18.1x | 49 |
Quick answers to the most common questions about buying PFE stock.
The consensus price target for PFE is $28.5, close to the current price of $27.93 (2.0% implied move). Based on 39 analyst estimates, the stock appears fairly valued near current levels.
PFE has a consensus rating of "Hold" based on 39 Wall Street analysts. The rating breakdown is mixed, with 23 Hold ratings making up the largest segment. The consensus 12-month price target of $28.5 implies 2.0% upside from current levels.
With a forward P/E of 9.3892x, PFE trades at a relatively low valuation. The consensus target of $28.5 implies 2.0% appreciation, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $31 for PFE, while the most conservative target is $26. The consensus of $28.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $49 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
PFE is heavily covered by Wall Street, with 39 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 15 have Buy ratings, 23 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PFE stock forecast based on 39 Wall Street analysts shows a consensus price target of $28.5, with estimates ranging from $26 (bear case) to $31 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $37, with bear/bull scenarios of $23/$49.
Our quantitative valuation model calculates PFE's fair value at $37 (base case), with a bear case of $23 and bull case of $49. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.
PFE trades at a forward P/E ratio of 9.4x based on next-twelve-months earnings estimates compared to a trailing P/E of 20.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
PFE appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $28.5 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PFE analyst price targets range from $26 to $31, a 18% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $28.5 consensus represents the middle ground. Our model's $23-$49 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.